Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | EQL PHARMA AB: Methenamine Hippurate (branded as Altaromin©) have gained marketing approval in France | 1 | Cision News | ||
08.05. | EQL Pharma AB: Year-End Report April 2024 - March 2025 | 238 | GlobeNewswire (Europe) | Sales and operating profit growth, significant product acquisition completed, 11 new products, first deal outside Europe and graduation year passed
January - March 2025
Consolidated sales during... ► Artikel lesen | |
23.04. | Invitation to presentation in connection with EQL Pharma's year-end report, fourth quarter, 2024/25 | 1 | Cision News | ||
11.03. | EQL Pharma signs a distribution agreement with a large distributor in the GCC countries for Mellozzan (melatonin) | 1 | Cision News | ||
07.03. | EQL Pharma AB: New financial targets for the period 2024/25 - 2028/29 | 112 | GlobeNewswire (Europe) | EQL will shortly conclude the 5-year plan for 2020/21 - 2024/25. Thus, the Company today 7 March presents new financial targets for the period 2024/25 - 2028/29.
Our target is to increase sales at... ► Artikel lesen | |
24.02. | EQL PHARMA AB: Nomination committee for the 2025 Annual General Meeting | 1 | Cision News | ||
05.02. | EQL Pharma AB: Interim Report April - December 2024 | 153 | GlobeNewswire (Europe) | Sales and operating profit growth, significant product acquisition signed
October - December 2024
Consolidated sales during the third quarter, October to December amounted to SEK 92.2 (70.2) million... ► Artikel lesen | |
EQL PHARMA Aktie jetzt für 0€ handeln | |||||
31.01. | EQL Pharma AB completes the asset purchase of a product portfolio from Medilink A/S | 2 | Cision News | ||
29.01. | EQL Pharma invites to Capital Markets Day, March 7, 2025 | 3 | Cision News | ||
17.01. | EQL Pharma AB successfully issues senior secured bonds | 3 | Cision News | ||
13.01. | Invitation to presentation in connection with EQL Pharma's interim report, third quarter, 2024/25 | 2 | Cision News | ||
13.01. | EQL Pharma AB (publ) contemplates to issue senior secured bonds and publishes preliminary figures as of 31 December 2024 | 4 | Cision News | ||
06.11.24 | EQL Pharma AB: Interim Report April - September 2024 | 83 | GlobeNewswire (Europe) | Sales and operating profit growth, new products added to the pipeline
July - September 2024
Consolidated sales during the second quarter, July to September amounted to SEK 85.2 (59.6) million, an... ► Artikel lesen | |
19.08.24 | EQL Pharma AB: Bulletin from the annual general meeting in EQL Pharma AB on 19 August 2024 | 130 | GlobeNewswire (Europe) | Today, on 19 August 2024, the annual general meeting was held in EQL Pharma AB. A summary of the adopted resolutions follows below.
Resolution on adoption of accounts and allocation of the company's... ► Artikel lesen | |
08.08.24 | EQL Pharma AB: Interim Report April - June 2024 | 125 | GlobeNewswire (Europe) | Sales and operating profit growth, new products added to the pipeline
April - June
Consolidated sales during the first quarter, April to June amounted to SEK 82.8 (56.2) million, an increase of 47%.... ► Artikel lesen | |
04.07.24 | Nasdaq Stockholm welcomes EQL Pharma to the Main Market | 282 | GlobeNewswire | Stockholm, Jul 4, 2024 - Nasdaq (Nasdaq: NDAQ) announces that trading in the
shares of EQL Pharma AB (ticker name: EQL) will commence today on the Nasdaq
Stockholm Main Market. EQL Pharma is a Small... ► Artikel lesen | |
02.07.24 | Nasdaq Stockholm AB: Listing of EQL Pharma AB on Nasdaq Stockholm | 250 | GlobeNewswire | On request of EQL Pharma AB, company registration number 556713-3425, Nasdaq
Stockholm has admitted the company's shares to trading with effect from July 4,
2024.
As per today's date the company has... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
VERTEX PHARMACEUTICALS | 378,70 | +0,49 % | Vertex Pharmaceuticals Incorporated (VRTX) Benefited from the Launch of its New Drug | ||
UNITED THERAPEUTICS | 243,00 | +0,12 % | UNITED THERAPEUTICS Corp - 8-K, Current Report | ||
CATALYST PHARMACEUTICALS | 18,655 | +0,24 % | Catalyst Pharma: Viel Wachstum für wenig Geld? | Die meisten Biotech-Aktien sind vor allem eins: hochspekulativ. Catalyst Pharma beweist jedoch, dass es auch anders geht - mit realen Gewinnen und nachhaltigem Wachstum Den vollständigen Artikel lesen... ► Artikel lesen | |
INDIVIOR | 11,500 | -4,17 % | Indivior beruft Tony Kingsley in den Vorstand | ||
CAMURUS | 54,75 | -0,09 % | Camurus AB: Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients | CAM2029 reduces liver and cyst volume growth compared to placebo Well tolerated with no new or unexpected safety findingsA follow-up Phase 3 study will be discussed with regulatory authoritiesLUND... ► Artikel lesen | |
BAYER | 26,975 | +2,64 % | Neuer Biotech-Boom entfacht: Evotec, BioNxt, Bayer, Novo Nordisk und Formycon vor dem nächsten Kursschub? | Die Biotechnologie-Branche erlebt derzeit eine bemerkenswerte Renaissance. Innovationen in der personalisierten Medizin, Fortschritte bei mRNA-Technologien sowie neue Therapieansätze gegen Krebs und... ► Artikel lesen | |
MERCK KGAA | 112,65 | +0,90 % | MilliporeSigma and "Abbott Elementary" Inspire Students' Curiosity With Hands-On STEM | NORTHAMPTON, MA / ACCESS Newswire / June 25, 2025 / Between September 2024 and April 2025, MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, teamed up with... ► Artikel lesen | |
NOVO NORDISK | 58,70 | +0,09 % | Buy or Goodbye?: Hellofresh, Tesla, Novo Nordisk und Zalando - Die Analystenstimmen des Tages | © Foto: Steffen Trumpf/dpaHellofresh, Tesla, Novo Nordisk und Zalando: So bewerten Top-Analysten die Aktien. Ein Überblick.JPMorgan senkt das Kursziel für Hellofresh Die US-Bank JPMorgan hat das Kursziel... ► Artikel lesen | |
PFIZER | 20,665 | +0,02 % | Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen | ||
EYENOVIA | 10,960 | +38,91 % | Eyenovia launches validator node for Hyperliquid blockchain | ||
ROCKET LAB | 30,200 | -0,10 % | Rocket Lab Corporation: Rocket Lab to Launch Electron Mission for European Space Agency's Next-Generation Navigation System | Rocket Lab Corporation (Nasdaq: RKLB) ("Rocket Lab" or the "Company"), a global leader in launch services and space systems, today announced it has been selected to launch a dedicated Electron mission... ► Artikel lesen | |
ASTRAZENECA | 120,05 | +0,42 % | Kaum Impulse für die AstraZeneca plc-Aktie (60,9091 €) | Der Kurs der der AstraZeneca plc-Aktie kommt kaum von der Stelle. Die Aktie kostete zuletzt 70,78 US-Dollar. Die Wertschätzung der Investoren für die Aktie von AstraZeneca plc hat sich heute kaum verändert.... ► Artikel lesen | |
DERMAPHARM | 34,750 | 0,00 % | EQS-DD: Dermapharm Holding SE: Dr. Andreas Eberhorn, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
24.06.2025 / 16:45... ► Artikel lesen | |
ELI LILLY | 670,70 | -1,27 % | Eli Lilly and Company: Lilly declares third-quarter 2025 dividend | INDIANAPOLIS, June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2025... ► Artikel lesen | |
SANOFI | 82,30 | +0,01 % | Minimale Kursveränderung bei Sanofi SA-Aktie (82,73 €) | Wenig Kursbewegung zur Stunde bei dem Anteilsschein von Sanofi SA . Das Wertpapier notiert aktuell bei 82,73 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei dem Anteilsschein von... ► Artikel lesen |